Modus Therapeutics

We're a Swedish biotech company developing #sevuparin for diseases with high unmet medical need, for patients with #sepsis and #septicshock.

[Modus Therapeutics @Modus_Tx]

We look forward to presenting new data on #sevuparin at the @EHA_Hematology Congress, demonstrating its potential to treat hepcidin-related disorders such as #anemia in chronic kidney disease and other chronic inflammatory disorders.

Click to read more: https://t.co/ZTkmqJfLDi

[Modus Therapeutics @Modus_Tx]

Our CEO is attending @LSXLeaders #WorldCongress in London this week. We look forward to discussing the progress of our lead candidate, sevuparin, with #lifescience leaders as we work towards initiating a Phase 2a study to evaluate #sevuparin as a potential treatment for #sepsis

[Modus Therapeutics @Modus_Tx]

We will join representatives from around the globe at the #WorldSepsisCongress 2023, where the theme is One Global Health Threat: #Sepsis, Pandemics, and Antimicrobial Resistance, to discuss the role of the emerging #technologies designed to treat and raise awareness of sepsis.

[Modus Therapeutics @Modus_Tx]

Our CEO is attending #BIOEuropeSpring this week to discuss the company's recent progress and the positive top-line data from our Phase 1b #clinicalstudy evaluating sevuparin as a potential new treatment for #sepsis, septic shock and other inflammatory diseases.
#biopharma

[Modus Therapeutics @Modus_Tx]

Our CFO will attend DNB Nordic Healthcare Conference to discuss the potential of #sevuparin in treatment of #sepsis/septic shock, a serious and often fatal condition.
Sevuparin is currently being evaluated in Phase 1b LPS provocation study, a well-established #clinical model.

[Modus Therapeutics @Modus_Tx]

Vad brinner vi för? Varför skall man investera i Modus?
Vår VD, John Öhd, ger svar på relevanta frågor rörande Modus och vår utveckling av sevuparin för sepsis och septisk chock.

https://t.co/PIXVg6Pztj

#biotech #sepsis

[Modus Therapeutics @Modus_Tx]

Our CEO will give a company presentation at @EP_Access' Temadag: HealthCare following the successful completion of recruitment into its Phase 1b #clinical study evaluating sevuparin for treatment of #sepsis.
Watch the Swedish presentation live here: https://t.co/EDKrFhjQvz

[Modus Therapeutics @Modus_Tx]

Our CEO, John Öhd, will present at Stora Aktiedagen in Stockholm on 30 November to discuss Modus’ development of sevuparin for #sepsis and septic shock.

Watch the Swedish presentation live at 14.30-15.00 CET: https://t.co/TJR8HeeLpc
#biotech

[Modus Therapeutics @Modus_Tx]

We're excited to be attending #BIOEurope in Leipzig, Germany this week to discuss recent progress in our Phase 1b trial investigating our lead asset, #sevuparin, for the treatment of #sepsis and #septicshock and learn about cutting-edge science in the #biotech space

[Modus Therapeutics @Modus_Tx]

Research in 2020 by @WHO_Europe_VPI revealed that 1 in 5 deaths worldwide are estimated to be due to #sepsis and septic shock.

Watch to learn how #sevuparin could be a potential treatment to meet these diseases extremely high unmet need. #clinicaltrials https://t.co/xyBaBYKdmf

[Modus Therapeutics @Modus_Tx]

We're thrilled to attend @NLifeScience Days on 29 September 2022. Meet with us to discuss the potential of #sevuparin to transform the treatment of #sepsis, #septicshock and other inflammatory diseases.
#NLS2022
Click to register at NLS Days: https://t.co/X0WTpnSlS1

[Modus Therapeutics @Modus_Tx]

In collaboration with @imperialcollege & @wellcometruste the SEVUSMART Phase 1 #clinical trial will evaluate #sevuparin in severe #malaria. This drug has already shown promising effects on the malaria parasite in patients with uncomplicated malaria
https://t.co/ohIUlh1ljc

[Modus Therapeutics @Modus_Tx]

We're now a proud signatory of @GlobalSepsis World Sepsis Declaration aiming to increase global, political and public awareness, to dramatically decrease the incidence of #sepsis by 2030 by improving #healthcare intervention and access to treatment
#lifescience #support

[Modus Therapeutics @Modus_Tx]

Today is #WorldSepsisDay. Dedicated to providing new, improved #sepsis treatment, #clinical stage candidate #sevuparin is gearing up toward Ph2 trials. Sepsis affects approx. 49m globally each year, it's the no.1 cause for hospital readmissions & costs $22b a year in the US alone

[Modus Therapeutics @Modus_Tx]

As we approach #WorldSepsisDay, we remain focused on building awareness of #sepsis and its complications.
We believe it's crucial to support the development of new treatment options as we progress #clinicaltrials for potential first-in-class therapy #sevuparin.

[Modus Therapeutics @Modus_Tx]

Our CFO, Claes Lindblad, will be presenting at @LSXLeaders Nordic Congress, 2022!
We look forward to discussing the potential of #sevuparin as we move closer to finalising recruitment of its Phase 1b #clinicalstudy for treatment of #sepsis
#sepsistreatment #sepsisawareness

[Modus Therapeutics @Modus_Tx]

This Wednesday we are attending Swiss Nordic Bio 2022!
We look forward to discussing the development of #sevuparin for treatment of #sepsis with investors and other Nordic and Swiss #lifescience companies.
Get in touch to arrange a meeting.
https://t.co/RP165uYRBP

[Modus Therapeutics @Modus_Tx]

Our lead product, #sevuparin is an innovative drug with a multimodal mechanism of action including anti-inflammatory & anticoagulation effects to treat #sepsis #sepsisshock & other inflammatory diseases.

Click to read about our UK & US #clinicalresearch:
https://t.co/we1pYshD5x

[Modus Therapeutics @Modus_Tx]

2022 will be the most important year in our Company’s history!
Having developed compound that can revolutionise the treatment of #sepsis, #sepsisshock and systematic inflamation, this year we initiate our pivotal Phase II #clinicalstudy for #sevuparin.

https://t.co/4l61jFTb4v

[Karolinska Institutet @karolinskainst]

Professor Johan von Schreeb has been named Head of KI’s Health Emergency and Pandemic Science Center. The aim is to find connections between groups and people and increase preparedness for a new pandemic or health crisis.
https://t.co/88bWtKQLZQ